ENVALITH
株式会社ソラスト logo

Solasto Corporation

6197Prime MarketServices

株式会社ソラスト logo
Solasto Corporation6197

Medical Business

The Group's largest segment, providing outsourced medical administrative services and staffing to medical institutions

PeriodCurrentPreviousChange
Net sales (FY2025 full year)¥73,834 million¥71,214 million
Operating profit (FY2025 full year)¥4,173 million¥4,388 million
Operating margin (FY2025 full year)5.7%6.2%
Medical outsourcing net sales (FY2025 full year)¥65,666 million¥63,013 million
Medical staffing net sales (FY2025 full year)¥6,305 million¥6,634 million
Segment assets (end of FY2025)¥10,773 million¥10,451 million

Business Details

Provides medical administrative services such as reception, billing, and medical fee claims, medical office peripheral services such as physician clerical assistance and nursing assistance, and hospital management support services such as hospital management consulting and IT services to medical institutions nationwide, through outsourcing and staffing arrangements. From FY2025, the Smart Hospital Business has been integrated into this segment. This is the Group's largest segment, accounting for approximately 52.3% of consolidated net sales.

Recent Overview

Net sales increased on the effect of price revisions, but operating profit declined due to strengthened treatment improvement and IT investments

In FY2025, net sales in the Medical Business increased 3.7% year on year to ¥73,834 million, driven by progress in price revision negotiations for existing outsourced operations exceeding the prior year. Operating profit, however, decreased 4.9% year on year to ¥4,173 million (operating margin of 5.7%), despite the price revision effect exceeding that of the prior year, due to increased investment in employee skills development and treatment improvement as well as new IT investments. From FY2025, the Smart Hospital Business has been integrated into this segment.

Key Products

service
Medical Administrative Services (Outsourcing)

Recorded net sales of ¥65,666 million in FY2025 as Medical Outsourcing. The main revenue driver was progress in price revision negotiations for existing outsourced operations.

service
Medical Staffing

Recorded net sales of ¥6,305 million in FY2025 as Medical Staffing. Dispatches specialized personnel such as medical administrative and nursing assistance staff to medical institutions.

service
Hospital Management Support Services / Smart Hospital Business

From FY2025, the Smart Hospital Business, previously classified under Others, was integrated into the Medical Business segment. Provides services to support the advancement and digitalization of hospital management.

service
Education Business

Operates training courses and skills certification examinations aimed at developing medical administrative personnel. Integrated into the Medical Business segment.

Growth Drivers

  • Continued progress in price revision negotiations for existing outsourced operations (progress in FY2025 exceeded the prior year)
  • Stable trend in demand for outsourcing of medical administrative work among medical institutions, primarily hospitals
  • Business synergies from integrating the Smart Hospital Business into the Medical Business segment
  • Productivity improvements and reductions in SG&A expenses through transition to next-generation operations
  • Promotion of next-generation outsourcing business development and evolution of the solutions business under the medium-term management plan

Risks

  • Increased costs from the strategic strengthening of investment in employee treatment improvement and human resource development (operating margin declined to 5.7% in FY2025)
  • Short-term increase in cost burden from new IT investments (including renewal of next-generation IT infrastructure)
  • Difficulty in timely and appropriate hiring of personnel in the medical administrative and hospital management fields (a key challenge across the industry)
  • Declining trend in medical staffing net sales (¥6,305 million in FY2025, down 5.0% year on year)
  • Non-disclosure of next-period earnings forecasts due to the planned delisting associated with the MBO, reducing transparency of the medium- to long-term business plan

Last updated: June 23, 2026